Product Datasheet  
MLH1 Antibody  
Catalog Number: 48713  
Technical:tech@swbio.com  
Information:info@swbio.com  
Description  
  • host_species：  
  • Rabbit
  • Amount：  
  • 100μgμg
  • Swiss-Prot No.：  
  • Swiss-Prot#:P40692
  • Form of Antibody：  
  • 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.
  • Storage：  
  • Store at -20˚C
  • Immunogen：  
  • recombinant protein
  • reactivity：  
  • Hu, Ms, Rt
  • appl_detail：  
  • WB: 1:1,000
    IHC: 1:50-1:100
    ICC: 1:50-1:200

    FC: 1:50-1:100
  • other_names：  
  • COCA 2 antibody
    COCA2 antibody
    DNA mismatch repair protein Mlh1 antibody
    FCC 2 antibody
    FCC2 antibody
    hMLH 1 antibody
    hMLH1 antibody
    HNPCC 2 antibody
    HNPCC antibody
    HNPCC2 antibody
    MGC5172 antibody
    ML
  • Purification：  
  • ProA affinity purified
  • Specificity：  
  • Applications：  
  • WB, ICC/IF, IHC, IP, FC
  • Background：  
  • DNA-mismatch repair (MMR) is an essential process in maintaining genetic stability. Lack of a functional DNA-mismatch repair pathway is a common characteristic of several different types of human cancers, either due to an MMR gene mutation or promoter methylation gene silencing. MLH1 is an integral part of the protein complex responsible for mismatch repair and is expressed in lymphocytes, heart, colon, breast, lung, spleen, testis, prostate, thyroid and gall bladder tissues, and is methylated in several ovarian tumors. Loss of MLH1 protein expression is associated with a mutated phenotype, microsatellite instability and a predisposition to cancer. In hereditary nonpolyposis colorectal cancer (HNPCC), an autosomal dominant inherited cancer syndrome that signifies a high risk of colorectal and various other types of cancer, the MLH1 gene exhibits a pathogenic mutation. Certain cancer cell lines, including leukemia CCRF-CEM, colon HCT 116 and KM12, and ovarian cancers SK-OV-3 and IGROV-1, show complete deficiency of MLH1, while MLH1 is expressed in 60% of melanomas, 70% of noninvasive squamous cell carcinomas and 30% of invasive squamous cell carcinomas.



 
© Signalway Biotechnology All Rights Reserved.